

New Innovations: Therapeutic Opportunities for Intellectual Disabilities

Jonathan D. Picker, MBChB, PhD^{1,2} and Christopher A. Walsh, MD, PhD¹

Intellectual disability is common and is associated with significant morbidity. Until the latter half of the 20th century, there were no efficacious treatments. Following initial breakthroughs associated with newborn screening and metabolic corrections, little progress was made until recently. With improved understanding of genetic and cellular mechanisms, novel treatment options are beginning to appear for a number of specific conditions. Fragile X and tuberous sclerosis offer paradigms for the development of targeted therapeutics, but advances in understanding of other disorders such as Down syndrome and Rett syndrome, for example, are also resulting in promising treatment directions. In addition, better understanding of the underlying neurobiology is leading to novel developments in enzyme replacement for storage disorders and adjunctive therapies for metabolic disorders, as well as potentially more generalizable approaches that target dysfunctional cell regulation via RNA and chromatin. Physiologic therapies, including deep brain stimulation and transcranial magnetic stimulation, offer yet another direction to enhance cognitive functioning. Current options and evolving opportunities for the intellectually disabled are reviewed and exemplified.

ANN NEUROL 2013;74:382-390

Treatment of intellectual disability (ID) is not a new phenomenon. The earliest references to ID date to the Papyrus of Thebes, circa 1500 BC, which includes the first identified records reporting disabilities of the mind.¹ Societal viewpoints, which have varied widely over time and between groups,^{2,3} largely determine the general response to people with ID, as well as the degree to which society invests in assisting affected individuals. From a financial perspective, ID is a major problem; in the United States in 2006, 11% of total government spending was for disability support, and this is expected to increase.⁴ With the realities of deinstitutionalization, society has had to accept a greater awareness of the issue, as individuals previously kept “away” are now integrated into families and the community. Thus, there are both financial and social imperatives to improve services for this group and provide stimulation for research into treatment.

Modern Understanding of Biology

ID is not a single entity, but reflects a myriad of different disorders. Genetic causes alone may number in the thou-

sands.⁵ This complicates our understanding, as we are not dealing with a discrete pathology but rather a collective with similar phenotypes. Furthermore, the terms used are themselves not truly descriptive. ID, the currently accepted American term (replacing mental retardation), is socially rather than scientifically derived, and limited in its precision. The new International Classification of Diseases (11th revision) categorization recommends “intellectual developmental disorder.”⁶ Our understanding of how learned memories are stored in the brain is still fragmentary,⁷⁻⁹ but learning processes appear to converge upon the ability to appropriately develop and modulate synaptic junctions in the brain.

Proper synaptic function, and hence normal intellectual function, depends upon two major components: (1) development of the nervous system and (2) functioning of the neurons and their network. Cognition appears to be particularly dependent upon both normal synaptic connections and the ability to modulate these connections in response to new stimuli, adapting as necessary. If the underlying anatomy of the brain is abnormal, for example, in a gross brain malformation like

View this article online at wileyonlinelibrary.com. DOI: 10.1002/ana.24002

Received May 22, 2013, and in revised form Jul 1, 2013. Accepted for publication Jul 29, 2013.

Address correspondence to Dr Walsh, Division of Genetics, Boston Children's Hospital, 3 Blackfan Circle, Boston, MA 02115. E-mail: christopher.walsh@childrens.harvard.edu

From the ¹Division of Genetics, Boston Children's Hospital, and Howard Hughes Medical Institute; ²Departments of Pediatrics and Neurology, Harvard Medical School, Boston, MA.

holoprosencephaly, the abnormal anatomy precludes the correct neural circuitry. Malformations affecting later developmental stages, such as neuronal migration disorders, similarly result in ID by disrupting normal patterns of synaptic connectivity.¹⁰ However, the majority of genetic causes of ID appear to disrupt the essence of the neuron's function, namely, its ability to send effective signals to other neurons. This effect is the strengthening (long-term potentiation) or weakening (long-term depression) of specific synaptic connections and their ability to be further altered in response to future stimuli.¹¹ This appears to be the basis upon which memory and response to learning can occur, as stimuli and responses are trained into specific routes. Defects in this ability to control synaptogenesis underlies many intellectual disabilities.^{12–14}

The failure of appropriate signaling between neurons across the synaptic junctions of dendritic branches is the central deficit in many cases of ID, as increasing data show. Perhaps the best example is fragile X. The FMRP protein product of the fragile X gene, *FMR1*, is critical to dendritic, and hence synaptic, maintenance and plasticity. FMRP transports critical RNA transcripts from the nucleus to dendrites.¹⁵ It also regulates translation of these transcripts by inhibition of the mGluR5 glutamate receptor.¹⁶ This receptor stimulates sp6 kinase translation for production of the proteins which create the dendritic outgrowths that interface with other neurons and allow signals to cross at the dendritic synaptic junction. Normally, this process is carefully regulated. In fragile X, the loss of FMRP results in unfettered mGluR5 activity and elevated protein translation.^{17–19} Abnormal protein translation is associated with abnormal dendritic morphology and abnormal patterns of synaptic plasticity, with profound effects on the capacity of affected individuals to learn and respond appropriately. An increasing number of genes linked to ID, involving a range of synaptic mechanisms, are being identified, whether they affect synaptogenesis directly^{20–26} or regulate anatomical patterns or consequent functioning.^{27,28} These pathways offer targeted treatment opportunities that focus on the molecular underpinnings of ID.

Currently Available Therapies

Much of current treatment is focused on environmental optimization. This includes individualized education plans, as well as minimizing complicating comorbidities (visual, sleep, pain, etc). This approach has provided significant improvements, as exemplified by the improved prognosis for Down syndrome.^{29,30} Although central to current management, it is not curative.

Specific treatments for improving ID at a biological level do exist, and have been around for some time. For example, dietary restriction for newborns identified with phenylketonuria (PKU) [who if left untreated develop an intelligence quotient of <30] were first attempted by Bickel >50 years ago.³¹ Successful treatment of PKU has become a paradigm for newborn screening and has produced a generation of healthy adults with PKU. Preventative treatment can take place even earlier; examples of prenatal treatments include education around avoidance of neurotoxic compounds such as alcohol or treatment of maternal hypothyroidism.³² Preventative therapies have changed the way we manage pregnancy and newborns, and within the inborn errors of metabolism community, instituting guided management at diagnosis has improved outcomes for a range of disorders.^{33–35} For some disorders, such as Hurler syndrome, newborn screening offers early diagnosis with the opportunity for meaningful treatment for cognition.³⁶ The potential benefit is less clear for disorders for which cognitive treatments are not yet available, such as Rett syndrome³⁷ or fragile X, although other aspects of such disorders may benefit.³⁸

Enzyme replacement therapy (ERT) has improved care for some metabolic disorders. As alluded to above, when coupled with stem cell therapy as a treatment for Hurler syndrome (mucopolysaccharidosis type 1), very young children have shown improved cognition.³⁹ Interestingly, for previously lethal conditions such as Pompe disease, in which ERT has changed prognosis, there appears to be unexpected intellectual sparing. As glycogen stores accumulate in the brain and the ERT does not cross the blood–brain barrier, it was anticipated cognition would suffer, as seen in other storage disorders. However, this possibility fortunately appears not to have been realized, at least to midchildhood.^{40,41} Unfortunately, ERT and metabolic amelioration are often insufficient in other disorders. Cognitive deficits remain for many metabolic disorders despite treatments. Treatment may exert a partial effect, as for some with organic acidemias,⁴² but seems less efficacious in other conditions, such as tyrosinemia or the urea cycle defects.^{43,44} Some treatments aim to improve on existing therapies, such as sapropterin dihydrochloride (BH4) in PKU. Although dietary treatment is effective, it is challenging to maintain, and compliance falls off over time, which has consequent effects on higher cognitive functions. BH4, a cofactor for phenylalanine hydroxylase (the defective enzyme in most cases of PKU), has been shown to benefit some patients.^{45–47}




FIGURE 1: Relative positions of disorders in the upstream pathways and target regions of potential therapeutic agents currently undergoing clinical trials or under active research with a view toward clinical trials. [Color figure can be viewed in the online issue, which is available at www.annalsofneurology.org.]

Therapeutic Pipeline in 2013

Whereas the majority of clinical trials still focus on supportive management, such as treatment of epilepsy, pain, and comorbidities (see ClinicalTrials.gov for details), an increasing number of trials focus on treatment of the underlying defect, via re-equilibration of the biochemical imbalance that results from genetic mutations. This method of targeted treatments is currently in trial for a number of disorders, and may offer opportunities to directly improve cognition. The majority currently in trial share pathways involved in control of dendritic growth and synaptogenesis.

A critical question for these and other treatment options is when to intervene. For some disorders, where damage occurs early, such as PKU, the earlier the treatment the better; but for others, such as Rett syndrome or fragile X, this may not necessarily be the case.

Concern about potential iatrogenic damage to the developing brain of neuroactive treatments needs to be weighed against excessive delay, when reversibility of the damage may be limited. Timing for these treatments will likely be disease specific. However, as research trials work their way down the age spectrum, the optimal age for treatment initiation and duration of therapy will likely become clearer.

Fragile X

Fragile X is the most common inherited cause of ID, affecting 1 in 4,000 individuals. As discussed above, FMRP regulates dendritic growth, with the γ -

aminobutyric acidergic (GABAergic) system being especially sensitive. Lack of FMRP results in unimpeded mGluR5 activity, which causes aberrant dendritic development with mis-signaling, culminating clinically in ID, autism, and psychopathology.⁴⁸ This model offers several potential targets. First, GABAergic activity can be increased. The first trial indicating a favorable response using this targeted approach has been carried out using arbaclofen, a GABA_B agonist. Initial results in humans suggest improvement in social function and behavior in individuals with fragile X.⁴⁹ In addition, mGluR5-specific antagonist trials have begun (involving AFQ056, RO4917523, and STX107), with a view toward replacing the inhibitory effect of the missing FMRP activity. Although definitive data are not yet available, a phase I trial of the mGluR5 inhibitor fenobam has suggested promising efficacy based on a single dose.⁵⁰ Additionally, the antibiotic minocycline, a metalloproteinase inhibitor that seems to have an inhibitory effect on the mGluR5 receptor, appeared in a double-blind study to have some efficacy.^{51,52}

Mammalian Target of Rapamycin Pathway

Next to Fragile X, tuberous sclerosis (TS) has probably generated the most activity in the research world of translational neuroscience. TS is a multisystem disorder with significant central nervous system effects, including cognitive deficits. TS is caused by mutations in either *TSC1* or *TSC2*, which encode proteins that form a complex inhibiting activation of mammalian target of

rapamycin (mTOR).^{53,54} The protein mTOR, which regulates both mGluR5 and ERK—itsself a regulator of pS6kinase translation and central to RNA translation—was identified as a potential target for treatment by a number of groups.^{55,56} Several drugs targeting the mTOR pathway are in clinical trial or design, and show promise in both preclinical and clinical trials. These include rapamycin itself as well as related compounds.⁵⁷ At this time, everolimus, an inhibitor of mTOR, is currently in trial to assess its role in improving the neurocognitive function of individuals with TS. It is notable that the mTOR pathway interleaves with the fragile X pathway (as shown in Figure 1). Subsequently, a number of other relatively common disorders involving other steps that interact with this pathway have been identified.^{58–60} These disorders generally feature ID and autistic symptomatology.^{61,62} This genetic interconnectedness raises some hope that treatments to regulate the mTOR pathway may help at least some other ID/autistic disorders in which the pathway appears to be indirectly perturbed.⁴⁸

Rett Syndrome/MeCP2

Rett syndrome, a disorder that occurs mainly in girls, is characterized by regression, ID, and distinctive hand movements, and is caused by mutations in the *MeCP2* gene.⁶³ Milder mutations in *MeCP2* cause a variety of other ID syndromes in both males and females.⁶⁴ *MeCP2* encodes a protein that binds methylated DNA. As a regulator of transcription, it appears to have multiple roles, including regulating neural homeostasis genes.⁶⁵ In addition, it has a role in synaptogenesis, although by as yet unclear mechanisms.⁶⁶ Mouse models for Rett syndrome show abnormal paw movements remarkably analogous to the human defects, and in these mice replacement of *MeCP2* restored at least partial function.^{67,68} These mouse studies suggested that *MeCP2* does not have essential functions in brain development and that interventions put in place after development was complete could still have potential efficacy. Overexpression of the trophic factor BDNF in a Rett model mouse also appeared to ameliorate the deficit.⁶⁹ Insulinlike growth factor 1 (IGF-1) is a proxy growth factor with significant molecular and functional overlap with BDNF and the ability to cross the blood–brain barrier. It has a potential role in Rett syndrome, as it increased survival and function in the mouse model.⁷⁰ Following successful phase I studies,⁷⁰ a phase II study is underway with cognitive outcome as a secondary outcome measure. Deriving in part from this, NNZ-2566, a synthetic analogue of the N-terminus tripeptide, glycine–proline–glutamate of IGF-1 which has similar effects but better pharmacokinetic properties, is currently in phase I of a clinical trial.^{71–73}

Trisomy 21/Down Syndrome

Trisomy 21 is the most common genetic cause of ID. Despite the duplication of an entire chromosome, it is likely that only a small number of genes and other genetic elements are involved in the phenotype of Down syndrome. Immunohistopathology and mouse model studies have identified candidate genes of interest, as well as pathologies that may be amenable to interventions. Vitamin E has been suggested, in some studies, to have utility in Alzheimer disease,^{74,75} and is currently in trial to see if it will slow the cognitive decline of older adults with Down syndrome who develop a precocious and severe form of AD in almost all cases. A study using memantine, a glutamine antagonist, suggested limited cognitive improvement in verbal memory in adults with Down syndrome; however, confirmation is required.⁷⁶ Perhaps the most interesting direction is the use of agents such as epigallocatechin gallate, which is a polyphenol that modulates *DYRK1A* gene function. *DYRK1A* is located on chromosome 21 and is overexpressed in Down syndrome, and was previously shown to be associated with neurofibrillary tangles and splicing regulation.^{77,78}

Unmet Needs

Three primary areas remain particularly challenging for development of treatments. These are: (1) major congenital structural brain lesions (eg, holoprosencephaly, hydrocephalus, and other lesions impacting gross anatomy), (2) ID of unknown etiology, and (3) untreated consequences of known disorders, such as neurodegenerative conditions and other causes of neural damage (eg, inborn errors of metabolism such as methylmalonic acidemia and others, kernicterus, etc).

Hopefully, as understanding of ID continues to improve and opportunities for specific disorders are developed, the ramifications of these developments will extend to these as yet unaided areas. For this, it may also be that new perspectives must emerge before we can begin to tackle the problem therapeutically.

Possible New Directions for Research

Conventional Drugs, New Uses

As awareness of the underlying neurobiochemical pathway deficits improves, possible uses for already-approved medications are increasingly being realized. For example, application of targeted drugs such as lithium and baclofen have shown some improved cognitive performance in a Down syndrome mouse model.^{79–81}

MicroRNA

MicroRNAs are a class of noncoding RNAs that bind to mRNA and regulate their translation. Over half of microRNAs are neurally expressed.⁸² Many appear to

have broad regulatory roles in cognitive processes, including regulation of neuroplasticity⁸³ and protein levels (eg, BDNF and the N-methyl-D-aspartate receptor NR2A in ID disorders⁸⁴). They may function as intermediate molecules in regulatory functioning of critical genes such as *MeCP2* in Rett syndrome⁸⁵ or for FMRP in controlling dendritic spine morphology in animal models of fragile X.⁸⁶ Therapeutic microRNAs, acting at the ribosome, may inhibit indiscriminate translation of mRNA moieties with reacquisition of control of spine morphology in fragile X.⁸⁷ With respect to Down syndrome, overexpression of chromosome 21-derived microRNAs appears to downregulate *MeCP2*, with subsequent decrease in *Mef2c* and *Creb1*, all involved in cognitive processing.⁸⁸ The potential to regulate genes via microRNA manipulation is well demonstrated in research settings and is being studied with interest for potential therapeutic possibilities.

Stem Cell Therapies

Although stem cell treatment for ID has caught the public imagination, and is offered in unregulated markets, the potential dangers remain unclarified. Additionally, the efficacy of such treatments at present does not match the long-term promise.^{89,90} Despite this, there is potential for good. Remarkably, animal studies suggest that the relatively undifferentiated, evolving cortex of neonates and infants may support some ability for structural brain repair as well as cognitive improvement in hypoxic-ischemic damaged mice pups following intranasal mesenchymal stem cell administration.^{91,92} Intranasal delivery may also serve as a means to deliver therapeutic molecules.^{93,94}

Transgenics

For genetic causes of ID, animal models have repeatedly shown the potential for this treatment. Safety concerns are significant, however,⁹⁵ and focus has been on developing safe vectors.⁹⁶ Clinical trials are again underway for disorders severe enough to merit the potential risks, including Sanfilippo syndrome type A among others.

Small Molecule Therapies

HISTONE DEACETYLASE INHIBITORS. Histone acetylation appears to be involved in memory formation; its level increases in the brain following learning.^{97,98} Many ID disorders associated with deficient memory formation, including Rubinstein-Taybi syndrome (RTS) and fragile X syndrome, show decreased histone acetylation.⁹⁹ There are numerous histone deacetylation (HDAC) moieties; this offers an opportunity to target according to need. The potential role is exemplified by a mouse model of RTS via inhibition of targeted HDAC, which restored a

range of memory and cognitive functioning deficits in these mice.^{100,101} From a preventative perspective, a range of HDAC inhibitors offers promise to protect against cerebral ischemic damage. The potential utility of this applies to neonates as well as older people. Evidence is emerging that HDAC inhibitors provide protection via enhancing angiogenesis, neurogenesis, and neuronal migration.¹⁰² Interestingly, carbon monoxide appears to have a similar role, and has been similarly proposed as a potential therapeutic agent; in both cases, the transcription factor Nrf2 is noted to be increased and is proposed as the mediator.^{102,103}

GENTAMICIN/STOP CODON READTHROUGH MOLECULES.

For disorders with mutations resulting in premature stop codons, the possibility of suppressing the resultant nonsense-mediated mRNA decay exists. It has been known since 1964 that streptomycin alters ribosomal readthrough of the RNA code.¹⁰⁴ High concentrations of gentamicin and other aminoglycoside antibiotics were shown to bind to eukaryotic rRNA and allow low-frequency readthrough of premature stop codons,¹⁰⁵ precipitating further investigation. An early study suggesting promise in Hurler syndrome noted that there was a small increase in enzyme activity in fibroblast cell lines treated with gentamicin.¹⁰⁶ Attention, however, has largely focused on the role of PTC124, particularly with respect to trials in cystic fibrosis and Duchenne muscular dystrophy.¹⁰⁷ Theoretically, this could be applied to disorder caused by nonsense mutations resulting in premature stop codons, including ID disorders.^{108,109} It is to be hoped that, as new premature termination codon (PTC)-skipping compounds are developed, this avenue will evolve, as suggested by animal studies with the aminoglycoside NB84.¹¹⁰

STRESS INDUCTION. The stress response of cells across kingdoms is highly conserved, and developed to allow the cell to modulate a series of pathways involving DNA damage, protein stabilization, and energy processing in response to the environment. Disorders involving these pathways may therefore be amenable to therapies that invoke the stress response as a means to circumvent deficiencies. Thus, 4-phenylbutyrate and trichostatin A appear to normalize very long chain fatty acid levels. In a mouse model of X-linked adrenoleukodystrophy, stimulation of both mitochondrial and peroxisomal function via the stress-dependent rather than constitutive pathway offered biochemical circumvention for at least part of the toxic metabolic process.¹¹¹

ELECTROPHYSIOLOGY. Both deep brain stimulation and transcranial magnetic stimulation have been used to treat ID disorders, as well as to treat epilepsy, motor

anomalies, and psychopathology.^{112–115} The potential to directly alter regions with aberrant plasticity raises the novel question of whether specific elements of cognitive deficit may be amenable to such therapies in the future.

Summary

We live in an age when the opportunity for treatment of disorders previously thought of as intrinsic and immutable is evolving before us. As this promise is realized, it will herald a new human perspective that no longer accepts as inevitable the consequences of ID. A substantially improved ability to treat cognitive problems would be a breakthrough worthy to join the ranks of such medical revolutions as vaccinations, anesthesia, antiseptics, radiology, and antibiotics. Much work is still to be done, but the tools, understanding, and treatments are emerging in increasingly diverse and unexpected ways.

Acknowledgment

J.D.P. is supported by the Sircar-Dynan Fund. C.A.W. is supported by the Simons Foundation and Manton Center for Orphan Disease Research and grants from the NIH National Institute of Neurological Diseases and Stroke (R01 NS079277, RO1 NS032457, and R01 NS035129) and NIH National Institute of Mental Health (RO1 MH083565 and 1RC2MH089952). C.A.W. is an Investigator of the Howard Hughes Medical Institute. We thank Katherine Pawlowski, BA for editorial work.

Potential Conflicts of Interest

J.D.P.: grants/grants pending, Novartis; data safety monitor, Roche. C.A.W.: personal fees, Hoffman LaRoche, Novartis, Autism Consortium; patent, 13/991,451.

References

1. Scheerenberger RC. A history of mental retardation. Baltimore, MD: P.H. Brookes, 1983.
2. Scior K, Addai-Davis J, Kenyon M, Sheridan JC. Stigma, public awareness about intellectual disability and attitudes to inclusion among different ethnic groups. *J Intellect Disabil Res* (in press).
3. Sheridan J, Scior K. Attitudes towards people with intellectual disabilities: a comparison of young people from British South Asian and White British backgrounds. *Res Dev Disabil* 2013;34:1240–1247.
4. Braddock D. Braddock D. Public spending for disability in the United States: 1997–2006. Boston: Federal Reserve Bank of Boston. Paper presented at: Conference on Housing for People with Disabilities; February 4–5, 2010; Washington, DC.
5. Ellison JW, Rosenfeld JA, Shaffer LG. Genetic basis of intellectual disability. *Ann Rev Med* 2013;64:441–450.

6. Salvador-Carulla L, Reed GM, Vaez-Azizi LM, et al. Intellectual developmental disorders: towards a new name, definition and framework for “mental retardation/intellectual disability” in ICD-11. *World Psychiatry* 2011;10:175–180.
7. Grossberg S. Adaptive resonance theory: how a brain learns to consciously attend, learn, and recognize a changing world. *Neural Netw* 2013;37:1–47.
8. Grossberg S, Versace M. Spikes, synchrony, and attentive learning by laminar thalamocortical circuits. *Brain Res* 2008;1218:278–312.
9. Liljeholm M, O’Doherty JP. Contributions of the striatum to learning, motivation, and performance: an associative account. *Trends Cogn Sci* 2012;16:467–475.
10. Liu JS. Molecular genetics of neuronal migration disorders. *Curr Neurol Neurosci Rep* 2011;11:171–178.
11. Bear MF. Bidirectional synaptic plasticity: from theory to reality. *Philos Trans R Soc Lond B Biol Sci* 2003;358:649–655.
12. Grant SG. Synaptopathies: diseases of the synaptome. *Curr Opin Neurobiol* 2012;22:522–529.
13. Ho VM, Lee JA, Martin KC. The cell biology of synaptic plasticity. *Science* 2011;334:623–628.
14. Melom JE, Littleton JT. Synapse development in health and disease. *Curr Opin Genet Dev* 2011;21:256–261.
15. Bagni C, Greenough WT. From mRNP trafficking to spine dysmorphogenesis: the roots of fragile X syndrome. *Nat Rev Neurosci* 2005;6:376–387.
16. Bear MF, Huber KM, Warren ST. The mGluR theory of fragile X mental retardation. *Trends Neurosci* 2004;27:370–377.
17. Comery TA, Harris JB, Willems PJ, et al. Abnormal dendritic spines in fragile X knockout mice: maturation and pruning deficits. *Proc Natl Acad Sci U S A* 1997;94:5401–5404.
18. Niere F, Wilkerson JR, Huber KM. Evidence for a fragile X mental retardation protein-mediated translational switch in metabotropic glutamate receptor-triggered Arc translation and long-term depression. *J Neurosci* 2012;32:5924–5936.
19. Rudelli RD, Brown WT, Wisniewski K, et al. Adult fragile X syndrome. *Clinico-neuropathologic findings. Acta Neuropathol* 1985; 67:289–295.
20. Kirschstein T. Synaptic plasticity and learning in animal models of tuberous sclerosis complex. *Neural Plast* 2012;2012:279834.
21. Talos DM, Sun H, Zhou X, et al. The interaction between early life epilepsy and autistic-like behavioral consequences: a role for the mammalian target of rapamycin (mTOR) pathway. *PLoS One* 2012;7:e35885.
22. Dileone M, Profice P, Pilato F, et al. Enhanced human brain associative plasticity in Costello syndrome. *J Physiol* 2010;588:3445–3456.
23. Neves-Pereira M, Muller B, Massie D, et al. Deregulation of EIF4E: a novel mechanism for autism. *J Med Genet* 2009;46:759–765.
24. Andreadi C, Cheung LK, Giblett S, et al. The intermediate-activity (L597V)BRAF mutant acts as an epistatic modifier of oncogenic RAS by enhancing signaling through the RAF/MEK/ERK pathway. *Genes Dev* 2012;26:1945–1958.
25. McCubrey JA, Steelman LS, Chappell WH, et al. Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/Pten/Akt/mTOR cascades which alter therapy response. *Oncotarget* 2012;3:954–987.
26. Tumurkhuu M, Saitoh M, Takita J, et al. A novel SOS1 mutation in Costello/CFC syndrome affects signaling in both RAS and PI3K pathways. *J Recept Signal Transduct Res* 2013;33:124–128.
27. Bena F, Bruno DL, Eriksson M, et al. Molecular and clinical characterization of 25 individuals with exonic deletions of NRXN1 and comprehensive review of the literature. *Am J Med Genet B Neuropsychiatr Genet* (in press).
28. Duong L, Klitten LL, Moller RS, et al. Mutations in NRXN1 in a family multiply affected with brain disorders: NRXN1 mutations

- and brain disorders. *Am J Med Genet B Neuropsychiatr Genet* 2012;159B:354–358.
29. Mahoney G, Perales F, Wiggers B, Herman B. Responsive Teaching: early intervention for children with Down syndrome and other disabilities. *Downs Syndr Res Pract* 2006;11:18–28.
 30. Sanz MT, Menendez J. A study of the effect of age of onset of treatment on the observed development of Down's syndrome babies. *Early Child Dev Care* 1996;118:93–101.
 31. Bickel H, Gerrard J, Hickmans EM. Influence of phenylalanine intake on phenylketonuria. *Lancet* 1953;265:812–813.
 32. Downing S, Halpern L, Carswell J, Brown RS. Severe maternal hypothyroidism corrected prior to the third trimester is associated with normal cognitive outcome in the offspring. *Thyroid* 2012;22:625–630.
 33. Buyukgebiz A. Newborn screening for congenital hypothyroidism. *J Clin Res Pediatr Endocrinol* 2013;5:8–12.
 34. Joy P, Black C, Rocca A, Haas M, Wilcken B. Neuropsychological functioning in children with medium chain acyl coenzyme a dehydrogenase deficiency (MCADD): the impact of early diagnosis and screening on outcome. *Child Neuropsychol* 2009;15:8–20.
 35. Lindner M, Gramer G, Haege G, et al. Efficacy and outcome of expanded newborn screening for metabolic diseases—report of 10 years from South-West Germany. *Orphanet J Rare Dis* 2011;6:44.
 36. Scott CR, Elliott S, Buroker N, et al. Identification of infants at risk for developing Fabry, Pompe, or mucopolysaccharidosis-I from newborn blood spots by tandem mass spectrometry. *Journal of Pediatrics* (in press).
 37. Amir RE, Sutton VR, Van den Veyver IB. Newborn screening and prenatal diagnosis for Rett syndrome: implications for therapy. *J Child Neurol* 2005;20:779–783.
 38. Abrams L, Cronister A, Brown WT, et al. Newborn, carrier, and early childhood screening recommendations for fragile X. *Pediatrics* 2012;130:1126–1135.
 39. Eisengart JB, Rudser KD, Tolar J, et al. Enzyme replacement is associated with better cognitive outcomes after transplant in Hurler syndrome. *J Pediatr* 2013;162:375–380.e371.
 40. Ebbink BJ, Aarsen FK, van Gelder CM, et al. Cognitive outcome of patients with classic infantile Pompe disease receiving enzyme therapy. *Neurology* 2012;78:1512–1518.
 41. Spiridigliozzi GA, Heller JH, Kishnani PS. Cognitive and adaptive functioning of children with infantile Pompe disease treated with enzyme replacement therapy: long-term follow-up. *Am J Med Genet C Semin Med Genet* 2012;160:22–29.
 42. Martin-Hernandez E, Lee PJ, Micciche A, et al. Long-term needs of adult patients with organic acidemias: outcome and prognostic factors. *J Inherit Metab Dis* 2009;32:523–533.
 43. Krivitzky L, Babikian T, Lee H-S, et al. Intellectual, adaptive, and behavioral functioning in children with urea cycle disorders. *Pediatr Res* 2009;66:96–101.
 44. Thimm E, Richter-Werkle R, Kamp G, et al. Neurocognitive outcome in patients with hypertyrosinemia type I after long-term treatment with NTBC. *J Inherit Metab Dis* 2012;35:263–268.
 45. Cerone R, Andria G, Giovannini M, et al. Testing for tetrahydrobiopterin responsiveness in patients with hyperphenylalaninemia due to phenylalanine hydroxylase deficiency. *Adv Ther* 2013;30:212–228.
 46. Levy HL, Milanowski A, Chakrapani A, et al. Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study. *Lancet* 2007;370:504–510.
 47. Rohr FJ, Munier AW, Levy HL. Acceptability of a new modular protein substitute for the dietary treatment of phenylketonuria. *J Inherit Metab Dis* 2001;24:623–630.
 48. Ebert DH, Greenberg ME. Activity-dependent neuronal signalling and autism spectrum disorder. *Nature* 2013;493:327–337.
 49. Berry-Kravis EM, Hessl D, Rathmell B, et al. Effects of STX209 (arbaclofen) on neurobehavioral function in children and adults with fragile X syndrome: a randomized, controlled, phase 2 trial. *Sci Transl Med* 2012;4:152ra127.
 50. Berry-Kravis E, Hessl D, Coffey S, et al. A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. *J Med Genet* 2009;46:266–271.
 51. Leigh MJ, Nguyen DV, Mu Y, et al. A randomized double blind, placebo controlled trial of minocycline in children and adolescents with fragile X syndrome. *J Dev Behav Pediatr* 2013;34:147–155.
 52. Siller SS, Broadie K. Matrix metalloproteinases and minocycline: therapeutic avenues for fragile X syndrome. *Neural Plast* 2012;2012:124548.
 53. European Chromosome 16 Tuberous Sclerosis Consortium. Identification and characterization of the tuberous sclerosis gene on chromosome 16. *Cell* 1993;75:1305–1315.
 54. van Slegtenhorst M, de Hoogt R, Hermans C, et al. Identification of the tuberous sclerosis gene TSC1 on chromosome 9q34. *Science* 1997;277:805–808.
 55. Inoki K, Li Y, Zhu T, et al. TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. *Nat Cell Biol* 2002;4:648–657.
 56. Tee AR, Fingar DC, Manning BD, et al. Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling. *Proc Natl Acad Sci U S A* 2002;99:13571–13576.
 57. Sato A, Kasai S, Kobayashi T, et al. Rapamycin reverses impaired social interaction in mouse models of tuberous sclerosis complex. *Nat Commun* 2012;3:1292.
 58. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. *Nat Rev Cancer* 2007;7:295–308.
 59. Denayer E, Ahmed T, Brems H, et al. Spred1 is required for synaptic plasticity and hippocampus-dependent learning. *J Neurosci* 2008;28:14443–14449.
 60. Stiles BL. Phosphatase and tensin homologue deleted on chromosome 10: extending its PTENacles. *Int J Biochem Cell Biol* 2009;41:757–761.
 61. McBride KL, Varga EA, Pastore MT, et al. Confirmation study of PTEN mutations among individuals with autism or developmental delays/mental retardation and macrocephaly. *Autism Res* 2010;3:137–141.
 62. Gipson TT, Johnston MV. Plasticity and mTOR: towards restoration of impaired synaptic plasticity in mTOR-related neurogenetic disorders. *Neural Plast* 2012;2012:486402.
 63. Amir RE, Van den Veyver IB, Wan M, et al. Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. *Nat Genet* 1999;23:185–188.
 64. Moretti P, Zoghbi HY. MeCP2 dysfunction in Rett syndrome and related disorders. *Curr Opin Genet Dev* 2006;16:276–281.
 65. Adkins NL, Georgel PT. MeCP2: structure and function. *Biochem Cell Biol* 2011;89:1–11.
 66. Blackman MP, Djukic B, Nelson SB, Turrigiano GG. A critical and cell-autonomous role for MeCP2 in synaptic scaling up. *J Neurosci* 2012;32:13529–13536.
 67. Giacometti E, Luikenhuis S, Beard C, Jaenisch R. Partial rescue of MeCP2 deficiency by postnatal activation of MeCP2. *Proc Natl Acad Sci U S A* 2007;104:1931–1936.
 68. Guy J, Gan J, Selfridge J, et al. Reversal of neurological defects in a mouse model of Rett syndrome. *Science* 2007;315:1143–1147.
 69. Chang Q, Khare G, Dani V, et al. The disease progression of Mecp2 mutant mice is affected by the level of BDNF expression. *Neuron* 2006;49:341–348.

70. Pini G, Scusa MF, Congiu L, et al. IGF1 as a potential treatment for Rett syndrome: safety assessment in six Rett patients. *Autism Res Treat* 2012;2012:679801.
71. Guan J, Gluckman PD. IGF-1 derived small neuropeptides and analogues: a novel strategy for the development of pharmaceuticals for neurological conditions. *Br J Pharmacol* 2009;157:881–891.
72. Saura J, Curatolo L, Williams CE, et al. Neuroprotective effects of Gly-Pro-Glu, the N-terminal tripeptide of IGF-1, in the hippocampus in vitro. *Neuroreport* 1999;10:161–164.
73. Wei HH, Lu XC, Shear DA, et al. NNZ-2566 treatment inhibits neuroinflammation and pro-inflammatory cytokine expression induced by experimental penetrating ballistic-like brain injury in rats. *J Neuroinflammation* 2009;6:19.
74. Farina N, Isaac MG, Clark AR, et al. Vitamin E for Alzheimer's dementia and mild cognitive impairment. *Cochrane Database Syst Rev* 2012;11:CD002854.
75. Li FJ, Shen L, Ji HF. Dietary intakes of vitamin E, vitamin C, and β -carotene and risk of Alzheimer's disease: a meta-analysis. *J Alzheimers Dis* 2012;31:253–258.
76. Boada R, Hutaff-Lee C, Schrader A, et al. Antagonism of NMDA receptors as a potential treatment for Down syndrome: a pilot randomized controlled trial. *Transl Psychiatry* 2012;2:e141.
77. Creau N. Molecular and cellular alterations in Down syndrome: toward the identification of targets for therapeutics. *Neural Plast* 2012;2012:171639.
78. de la Torre R, Dierssen M. Therapeutic approaches in the improvement of cognitive performance in Down syndrome: past, present, and future. *Prog Brain Res* 2012;197:1–14.
79. Contestabile A, Greco B, Ghezzi D, et al. Lithium rescues synaptic plasticity and memory in Down syndrome mice. *J Clin Invest* 2013;123:348–361.
80. Cramer N, Galdzicki Z. From abnormal hippocampal synaptic plasticity in down syndrome mouse models to cognitive disability in down syndrome. *Neural Plast* 2012;2012:1–12.
81. Kleschnevnikov AM, Belichenko PV, Gall J, et al. Increased efficiency of the GABAA and GABAB receptor-mediated neurotransmission in the Ts65Dn mouse model of Down syndrome. *Neurobiol Dis* 2012;45:683–691.
82. Cao X, Yeo G, Muotri AR, et al. Noncoding RNAs in the mammalian central nervous system. *Ann Rev Neurosci* 2006;29:77–103.
83. Khudayberdiev S, Fiore R, Schrott G. MicroRNA as modulators of neuronal responses. *Commun Integr Biol* 2009;2:411–413.
84. Edbauer D, Neilson JR, Foster KA, et al. Regulation of synaptic structure and function by FMRP-associated MicroRNAs miR-125b and miR-132. *Neuron* 2010;65:373–384.
85. Nomura T, Kimura M, Horii T, et al. MeCP2-dependent repression of an imprinted miR-184 released by depolarization. *Hum Mol Genet* 2008;17:1192–1199.
86. Xu B, Hsu PK, Karayiorgou M, Gogos JA. MicroRNA dysregulation in neuropsychiatric disorders and cognitive dysfunction. *Neurobiol Dis* 2012;46:291–301.
87. Darnell JC, Klann E. The translation of translational control by FMRP: therapeutic targets for FXS. *Nat Neurosci* (in press).
88. Kuhn DE, Nuovo GJ, Terry AV Jr, et al. Chromosome 21-derived microRNAs provide an etiological basis for aberrant protein expression in human Down syndrome brains. *J Biol Chem* 2010;285:1529–1543.
89. Molcanyi M, Bosche B, Kraitsy K, et al. Pitfalls and fallacies interfering with correct identification of embryonic stem cells implanted into the brain after experimental traumatic injury. *J Neurosci Methods* 2013;215:60–70.
90. Stone K. Experts urge caution over unregulated stem cell therapies. *Ann Neurol* 2012;71:A9.
91. Donega V, van Velthoven CT, Nijboer CH, et al. Intranasal mesenchymal stem cell treatment for neonatal brain damage: long-term cognitive and sensorimotor improvement. *PLoS One* 2013;8:e51253.
92. van Velthoven CT, van de Looij Y, Kavelaars A, et al. Mesenchymal stem cells restore cortical rewiring after neonatal ischemia in mice. *Ann Neurol* 2012;71:785–796.
93. Liu X. Clinical trials of intranasal delivery for treating neurological disorders—a critical review. *Expert Opin Drug Deliv* 2011;8:1681–1690.
94. Malerba F, Paoletti F, Capsoni S, Cattaneo A. Intranasal delivery of therapeutic proteins for neurological diseases. *Expert Opin Drug Deliv* 2011;8:1277–1296.
95. Jenks S. Gene therapy death—“everyone has to share in the guilt.” *J Natl Cancer Inst* 2000;92:98–100.
96. Romano G. Development of safer gene delivery systems to minimize the risk of insertional mutagenesis-related malignancies: a critical issue for the field of gene therapy. *ISRN Oncol* 2012;2012:616310.
97. Korzus E, Rosenfeld MG, Mayford M. CBP histone acetyltransferase activity is a critical component of memory consolidation. *Neuron* 2004;42:961–972.
98. Levenson JM, O'Riordan KJ, Brown KD, et al. Regulation of histone acetylation during memory formation in the hippocampus. *J Biol Chem* 2004;279:40545–40559.
99. Graff J, Tsai LH. The potential of HDAC inhibitors as cognitive enhancers. *Annu Rev Pharmacol Toxicol* 2013;53:311–330.
100. Alarcon JM, Malleret G, Touzani K, et al. Chromatin acetylation, memory, and LTP are impaired in CBP+/- mice: a model for the cognitive deficit in Rubinstein-Taybi syndrome and its amelioration. *Neuron* 2004;42:947–959.
101. Haettig J, Stefanko DP, Multani ML, et al. HDAC inhibition modulates hippocampus-dependent long-term memory for object location in a CBP-dependent manner. *Learn Mem* 2011;18:71–79.
102. Fessler EB, Chibane FL, Wang Z, Chuang DM. Potential roles of HDAC inhibitors in mitigating ischemia-induced brain damage and facilitating endogenous regeneration and recovery. *Curr Pharm Des* (in press).
103. Wang B, Cao W, Biswal S, Dore S. Carbon monoxide-activated Nrf2 pathway leads to protection against permanent focal cerebral ischemia. *Stroke* 2011;42:2605–2610.
104. Davies J, Gilbert W, Gorini L. Streptomycin, suppression, and the code. *Proc Natl Acad Sci U S A* 1964;51:883–890.
105. Burke JF, Mogg AE. Suppression of a nonsense mutation in mammalian cells in vivo by the aminoglycoside antibiotics G-418 and paromomycin. *Nucleic Acids Res* 1985;13:6265–6272.
106. Keeling KM, Brooks DA, Hopwood JJ, et al. Gentamicin-mediated suppression of Hurler syndrome stop mutations restores a low level of alpha-L-iduronidase activity and reduces lysosomal glycosaminoglycan accumulation. *Hum Mol Genet* 2001;10:291–299.
107. Peltz SW, Morsy M, Welch EM, Jacobson A. Ataluren as an agent for therapeutic nonsense suppression. *Ann Rev Med* 2013;64:407–425.
108. Buck NE, Wood LR, Hamilton NJ, et al. Treatment of a methylmalonyl-CoA mutase stopcodon mutation. *Biochem Biophys Res Commun* 2012;427:753–757.
109. Popescu AC, Sidorova E, Zhang G, Eubanks JH. Aminoglycoside-mediated partial suppression of MECP2 nonsense mutations responsible for Rett syndrome in vitro. *J Neurosci Res* 2010;88:2316–2324.
110. Wang D, Belakhov V, Kandasamy J, et al. The designer aminoglycoside NB84 significantly reduces glycosaminoglycan accumulation associated with MPS I-H in the Idua-W392X mouse. *Mol Genet Metab* 2012;105:116–125.

111. Brose RD, Shin G, McGuinness MC, et al. Activation of the stress proteome as a mechanism for small molecule therapeutics. *Hum Mol Genet* 2012;21:4237–4252.
112. Deon LL, Kalichman MA, Booth CL, et al. Pallidal deep-brain stimulation associated with complete remission of self-injurious behaviors in a patient with Lesch-Nyhan syndrome: a case report. *J Child Neurol* 2012;27:117–120.
113. Lai KL, Lin CY, Liao KK, et al. Transcranial magnetic stimulation after conditioning stimulation in two adrenomyeloneuropathy patients: delayed but facilitated motor-evoked potentials. *Funct Neurol* 2006;21:141–144.
114. Oberman L, Ifert-Miller F, Najib U, et al. Transcranial magnetic stimulation provides means to assess cortical plasticity and excitability in humans with fragile x syndrome and autism spectrum disorder. *Front Synaptic Neurosci* 2010;2:26.
115. Xie T, Goodman R, Browner N, et al. Treatment of fragile X-associated tremor/ataxia syndrome with unilateral deep brain stimulation. *Move Disord* 2012;27:799–800.